Antibodies
17 December 2007
Auxilium Pharmaceuticals, Inc. Completes Enrollment in Two Phase III Clinical Trials of XIAFLEX(TM) for Dupuytren’s Contracture17 December 2007
Ablynx Reports Positive Phase I Results for Its Anti-Thrombotic Nanobody(R), ALX-008113 December 2007
WILEX announces positive result of the interim analysis for futility of its Phase III ARISER trial with RENCAREX(R)13 December 2007
Merck Announces Initiation of Phase II/III Clinical Trial of Atacicept in Lupus Nephritis11 December 2007
ThromboGenics Presents Results of the Phase I Trial of TB-402 at thePrestigious American Society of Hematology Annual Meeting10 December 2007
Seattle Genetics Reports Multiple Complete Remissions With SGN-33 in Acute Myeloid Leukemia at ASH10 December 2007
GlaxoSmithKline and OncoMed Pharmaceuticals Form Strategic Alliance to Develop Cancer Stem Cell Antibody Therapeutics10 December 2007
Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma10 December 2007
Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)10 December 2007
Biolex Researchers Present Results of Anti-CD20 Antibody With Optimized Glycosylation at ASH Conference10 December 2007
Genitope Corporation Presents New Data On Its Therapeutic Monoclonal Antibodies To Potentially Treat B-Cell Malignancies10 December 2007
MorphoSys Broadens Scope of Collaboration with GeneFrontier10 December 2007
PDL BioPharma Presents Data on Novel Monoclonal Antibody for Multiple Myeloma at the 2007 American Society of Hematology Annual Meeting10 December 2007
Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints10 December 2007
Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkin’s Lymphoma9 December 2007
ImmunoGen, Inc. Announces Encouraging Clinical Findings Reported at ASH Annual Meeting for TAP Compound AVE96336 December 2007
Raven biotechnologies, Inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies5 December 2007
Genentech Provides Update From Avastin FDA Advisory MeetingNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports